What is Javara?
Javara operates as a leading Integrated Research Organization (IRO), dedicated to facilitating clinical trial access at the point of care. By partnering with large healthcare organizations, Javara integrates research staff and infrastructure directly into clinical settings. This model leverages trusted physician relationships to access broad and diverse patient populations, ensuring high enrollment and retention rates for quality data delivery. The company's centralized resources and standardized operations are designed to enhance efficiencies, expedite study start-up, and improve outcomes, thereby reducing obstacles in the product approval pipeline. Javara is a pioneer of the Clinical Research as a Care Option (CRAACO) model, aiming to transform healthcare by connecting appropriate patients with suitable trials at the optimal time.
How much funding has Javara raised?
Javara has raised a total of $4.8M across 2 funding rounds:
Debt
$150K
Unspecified
$4.6M
Debt (2020): $150K with participation from PPP
Unspecified (2020): $4.6M, investors not publicly disclosed
Key Investors in Javara
PPP
Public-Private Partnership
What's next for Javara?
With a substantial enterprise-level funding context, Javara is positioned for significant scaling and operational expansion. The recent capital infusion is expected to bolster its infrastructure, enhance its technological capabilities, and broaden its network of healthcare partnerships. This strategic investment will likely enable Javara to further solidify its leadership in the CRAACO space, driving greater integration of clinical research into standard healthcare delivery and accelerating the development of new medical treatments. The focus will remain on optimizing data quality and patient access, reinforcing its role as a critical enabler in the pharmaceutical and healthcare industries.
See full Javara company page
